Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 1,534,529 |
|
|||||
| News | - | ||||||
| Day High | 16.96 | Low High |
|||||
| Day Low | 16.39 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| TG Therapeutics Inc | TGTX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.20 | 1.21% | 16.77 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 16.71 | 16.39 | 16.96 | 16.77 | 16.57 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 15,846 | 1,534,529 | US$ 16.71 | US$ 25,637,968 | - | 6.46 - 26.60 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:45:29 | 10 | US$ 16.75 | USD |
TG Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.59B | 154.42M | - | 233.66M | 12.67M | 0.08 | 204.51 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
TG Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TGTX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 15.80 | 17.67 | 15.63 | 16.58 | 1,978,580 | 0.97 | 6.14% |
| 1 Month | 16.38 | 17.8738 | 15.16 | 16.54 | 2,055,609 | 0.39 | 2.38% |
| 3 Months | 15.83 | 18.41 | 12.93 | 15.69 | 3,042,067 | 0.94 | 5.94% |
| 6 Months | 18.58 | 22.67 | 12.84 | 16.26 | 3,947,429 | -1.81 | -9.74% |
| 1 Year | 25.50 | 26.60 | 6.46 | 13.99 | 4,640,386 | -8.73 | -34.24% |
| 3 Years | 37.27 | 41.00 | 3.48 | 14.20 | 3,562,736 | -20.50 | -55.00% |
| 5 Years | 7.46 | 56.74 | 3.48 | 16.43 | 2,815,109 | 9.31 | 124.80% |
TG Therapeutics Description
| TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. |
